Journal of Biological Chemistry · 2003 · 32 citations · 14 references
Life SciencesBiochemistryPharmacologyBiochemical PharmacologyMetabolismPost-translational ModificationProtein OxidationProteolytic EnzymesProteolytic ProcessingArachidonic Acid MetabolitesCovalent Protein AdductsLysine Adduct FormationProteolytic Digestion AnalysisReactive Metabolite AdductsThrombin-mediated Platelet Activation
The product of oxygenation of arachidonic acid by the prostaglandin H synthases (PGHS), prostaglandin H2 (PGH2), undergoes rearrangement to the highly reactive γ-ketoaldehydes, levuglandin (LG) E2, and LGD2. We have demonstrated previously that LGE2reacts with the ε-amine of lysine to form both the levuglandinyl-lysine Schiff base and the pyrrole-derived levuglandinyl-lysine lactam adducts. We also have reported that these levuglandinyl-lysine adducts are formed on purified PGHSs following the oxygenation of arachidonic acid. We now present evidence that the levuglandinyl-lysine lactam adduct is formed in human platelets upon activation with exogenous arachidonic acid or thrombin. After proteolytic digestion of the platelet proteins, and isolation of the adducted amino acid residues, this adduct was identified by liquid chromatography-tandem mass spectrometry. We also demonstrate that formation of these adducts is inhibited by indomethacin, a PGHS inhibitor, and is enhanced by an inhibitor of thromboxane synthase. These data establish that levuglandinyl-lysine adducts are formed via a PGHS-dependent pathway in whole cells, even in the presence of an enzyme that metabolizes PGH2. They also demonstrate that a physiological stimulus is sufficient to lead to the lipid modification of proteins through the levuglandin pathway in human platelets. The product of oxygenation of arachidonic acid by the prostaglandin H synthases (PGHS), prostaglandin H2 (PGH2), undergoes rearrangement to the highly reactive γ-ketoaldehydes, levuglandin (LG) E2, and LGD2. We have demonstrated previously that LGE2reacts with the ε-amine of lysine to form both the levuglandinyl-lysine Schiff base and the pyrrole-derived levuglandinyl-lysine lactam adducts. We also have reported that these levuglandinyl-lysine adducts are formed on purified PGHSs following the oxygenation of arachidonic acid. We now present evidence that the levuglandinyl-lysine lactam adduct is formed in human platelets upon activation with exogenous arachidonic acid or thrombin. After proteolytic digestion of the platelet proteins, and isolation of the adducted amino acid residues, this adduct was identified by liquid chromatography-tandem mass spectrometry. We also demonstrate that formation of these adducts is inhibited by indomethacin, a PGHS inhibitor, and is enhanced by an inhibitor of thromboxane synthase. These data establish that levuglandinyl-lysine adducts are formed via a PGHS-dependent pathway in whole cells, even in the presence of an enzyme that metabolizes PGH2. They also demonstrate that a physiological stimulus is sufficient to lead to the lipid modification of proteins through the levuglandin pathway in human platelets. prostaglandin H2 synthase prostaglandin H2 liquid chromatography electrospray ionization tandem mass spectrometry levuglandin high performance liquid chromatography Prostaglandin H synthase (PGHS)1 catalyzes the oxygenation of arachidonic acid to the endoperoxide, prostaglandin H2 (PGH2). PGH2 is further metabolized to the prostanoids PGD2, PGE2, PGF2a, thromboxane A2, and prostacyclin by specific enzymes. Also, PGH2 in aqueous solutions undergoes non-enzymatic rearrangement to yield PGE2 and PGD2, and 207 of it rearranges to the highly reactive γ-ketoaldehydes, levuglandins (LG) E2 and D2(1Salomon R.G. Miller D.B. Raychaudhuri S.R. Avasthi K. Lal K. Levison B.S. J. Am. Chem. Soc. 1984; 106: 8296-8298Crossref Scopus (43) Google Scholar, 2Boutaud O. Brame C.J. Salomon R.G. Roberts II, L.J. Oates J.A. Biochemistry. 1999; 38: 9389-9939Crossref PubMed Scopus (60) Google Scholar) (Fig. 1). Levuglandins are known to react covalently with primary amines, such as the ε-amine of lysine, with proteins and with DNA (3Iyer R.S. Ghosh S. Salomon R.G. Prostaglandins. 1989; 37: 471-480Crossref PubMed Scopus (78) Google Scholar, 4Murthi K.K. Friedman L.R. Oleinick N.L. Salomon R.G. Biochemistry. 1993; 32: 4090-4097Crossref PubMed Scopus (58) Google Scholar). We have characterized the adducts that are formed by the reaction of lysine with LGE2or PGH2 (2Boutaud O. Brame C.J. Salomon R.G. Roberts II, L.J. Oates J.A. Biochemistry. 1999; 38: 9389-9939Crossref PubMed Scopus (60) Google Scholar, 5Brame C.J. Salomon R.G. Morrow J.D. Roberts II, L.J. J. Biol. Chem. 1999; 274: 13139-13146Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar), and knowledge of their structures has provided a basis for analysis of the adducts in protein digests utilizing liquid chromatography-tandem mass spectrometry. Utilizing this analytical approach, we have demonstrated formation of LG-lysine adducts on PGHS-1 and PGHS-2 following the oxygenation of arachidonic acid (6Boutaud O. Brame C.J. Chaurand P. Li J. Rowlinson S.W. Crews B.C. Ji C. Marnett L.J. Caprioli R.M. Roberts II, L.J. Oates J.A. Biochemistry. 2001; 40: 6948-6955Crossref PubMed Scopus (31) Google Scholar). Formation of covalent adducts also was observed with proteins co-incubated with PGHS and arachidonic acid. These findings formed the basis for a hypothesis that PGHS activity in cells could generate levuglandinyl adducts of proteins. Oxygenation of arachidonic acid by PGHS-1 in platelet microsomes has been shown to produce arachidonic acid-derived adducts of multiple proteins (7Wilson A.G. Kung H.C. Anderson M.W. Eling T.E. Prostaglandins. 1979; 18: 409-422Crossref PubMed Scopus (12) Google Scholar). Such labeling also has been reported in whole platelets (8Lecomte M. Lecocq R. Dumont J.E. Boeynaems J.M. J. Biol. Chem. 1990; 265: 5178-5187Abstract Full Text PDF PubMed Google Scholar) and is increased when thromboxane A2 synthase is inhibited. However, the reactive product of arachidonic acid that forms these protein adducts has not yet been characterized. We hypothesized that these adducts of platelet proteins are formed from LGE2 and LGD2. This report provides evidence that levuglandinyl-lysine adducts of proteins are formed in cells as a consequence of the oxygenation of arachidonic acid by a PGHS. Dazoxiben was a generous gift from Pfizer Ltd. (Sandwich, UK). Methanol was ordered from Burdick and Jackson (Muskegon, MI). Arachidonic acid, sodium citrate, citric acid, indomethacin, and butylated hydroxytoluene were purchased from Sigma. Sepharose 2B is from Amersham Biosciences (Uppsala, Sweden). OasisTM Sep-Pak cartridges were obtained from Waters Corp. (Milford, MA), and dimethyl formamide and trisphenylphosphine were from Aldrich. Pronase and aminopeptidase M from porcine kidney were from Calbiochem. Thrombin was obtained from Pharmingen. Human blood was obtained following a protocol approved by the Institutional Review Board of Vanderbilt University. Washed human platelets were isolated following the protocol described previously (9Boutaud O. Aronoff D.M. Richardson J.H. Marnett L.J. Oates J.A. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 7130-7135Crossref PubMed Scopus (209) Google Scholar). The blood was drawn with a syringe containing 5 ml of 3.87 sodium citrate (final volume: 50 ml), then centrifuged in plastic tubes at 300 × gfor 10 min at room temperature (23 °C). The supernatant (platelet-rich plasma) was acidified to pH 6.4 with 0.15 mcitric acid (10Lagarde M. Bryon P.A. Guichardant M. Dechavanne M. Thromb. Res. 1980; 17: 581-588Abstract Full Text PDF PubMed Scopus (154) Google Scholar) and then centrifuged at 1,000 × g for 10 min at room temperature. The pellet was resuspended with 5 ml of washing buffer (24.4 mm sodium phosphate, pH 6.5, 0.113m NaCl, 5.5 mm glucose). After 15 min at room temperature, the platelets were purified on a Sepharose 2B column equilibrated with washing buffer. The eluted platelets were counted with a Coulter counter and diluted with resuspension buffer (8.3 mm sodium phosphate, pH 7.5, 0.109 m NaCl, 5.5 mm glucose) for a final count of 600,000 platelets/ॖl. Washed platelets were then preincubated with indomethacin (final concentration of 100 ॖm), dazoxiben (final concentration of 10 ॖm), or vehicle for 30 min at room temperature. At this time, the platelets were activated by adding arachidonic acid (final concentration of 20 ॖm) or thrombin (final concentration of 1 Unit/ml) and incubated at room temperature for 15 min. After incubation, platelets were pelleted at 2,000 × g for 10 min at room temperature. After centrifugation, the LG-lysine lactam adduct was isolated from proteins and analyzed by LC MS/MS as described previously (5Brame C.J. Salomon R.G. Morrow J.D. Roberts II, L.J. J. Biol. Chem. 1999; 274: 13139-13146Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar, 11Bernoud-Hubac N. Davies S.S. Boutaud O. Montine T.J. Roberts II, L.J. J. Biol. Chem. 2001; 276: 30964-30970Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar). In short, 10 ml of cold ethanol (containing 50 mg/liter of butylated hydroxytoluene and 500 mg/liter of trisphenylphosphine) were added to the cell pellets, and the proteins were precipitated by centrifugation at 2,000 ×g for 10 min at 4 °C. Proteins were then reprecipitated in 10 ml of cold solution of methanol/chloroform 1:2 (v:v) and washed with 10 ml of methanol (each containing butylated hydroxytoluene and trisphenylphosphine). Then, partial digestion of proteins to single amino acid was performed using 3 mg of Pronase and 3 ॖl of aminopeptidase M (0.15 unit) per sample. After purification the LG-lysine lactam adduct was analyzed by LC MS/MS as described previously (5Brame C.J. Salomon R.G. Morrow J.D. Roberts II, L.J. J. Biol. Chem. 1999; 274: 13139-13146Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar, 6Boutaud O. Brame C.J. Chaurand P. Li J. Rowlinson S.W. Crews B.C. Ji C. Marnett L.J. Caprioli R.M. Roberts II, L.J. Oates J.A. Biochemistry. 2001; 40: 6948-6955Crossref PubMed Scopus (31) Google Scholar). The 13C-labeled internal standard was prepared by reaction of synthetic LGE2 (12Miller D.B. Raychaudhuri S.R. Avasthi K. Lal K. Levison B. Salomon R.G. J. Org. Chem. 1990; 55: 3164-3175Crossref Scopus (37) Google Scholar) and [13C]lysine; the LG-lysine lactam standard was then purified as described previously (11Bernoud-Hubac N. Davies S.S. Boutaud O. Montine T.J. Roberts II, L.J. J. Biol. Chem. 2001; 276: 30964-30970Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar). We examined the formation of LG-lysine lactam adducts on platelet proteins following oxygenation of exogenous arachidonic acid. Following proteolytic digestion of platelet proteins, the products were analyzed by LC MS/MS. Selected reaction monitoring was used to analyze the LG-lysine lactam fragment ions derived from the levuglandinyl moiety (m/z 332.1) and the lysyl moiety (m/z 84.1) of the adduct (5Brame C.J. Salomon R.G. Morrow J.D. Roberts II, L.J. J. Biol. Chem. 1999; 274: 13139-13146Abstract Full Text Full Text PDF PubMed Scopus (151) Google Scholar) (Fig.2). From platelets incubated with 20 ॖmarachidonic acid, both of these fragment ions are detected (Fig.3). The simultaneous elution of the two fragment ions concurrently with the [13C]LG-lysine lactam standard provides consistent evidence that identifies the LG-lysine lactam adduct. Preincubation of the cells with indomethacin for 30 min markedly reduces the formation of the LG-lysine lactam from 169 to 20 pg of lactam/1 × 109 platelets. These findings demonstrate that levuglandins are generated in human platelets in a PGHS-dependent fashion and form covalent adducts with proteins.Figure 3Characterization of the levuglandinyl-lysine adducts from platelets. Human platelets were pre-incubated with indomethacin 100 ॖm or vehicle for 30 min. After incubation with 20 ॖm arachidonic acid for 15 min, the proteins from human platelets were precipitated and digested to single amino acids by step-digestion with Pronase and aminopeptidase M. The adducts were purified by chromatography on an OasisTMcartridge followed by a reverse phase HPLC and then analyzed by LC/ESI MS/MS. Selected reaction monitoring chromatograms for the transitions of m/z 479.4 to the daughter ions m/z 84.1, and 332.1, representing the LG-lysine lactam adducts formed from arachidonic acid, and the transitions of m/z 485.4 to the daughter ions m/z 89.1, and 332.1, representing the internal standard LG-lysine lactam adducts formed with [13C]lysine, are shown. The fragment ion atm/z 84.1 that elutes earlier than the internal standard does not co-elute with a corresponding fragment at m/z 332.1 and, therefore, is derived from a different molecule, possibly one containing lysine.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Because of the theoretical possibility that activation of platelets with exogenous arachidonic acid might generate an amount of PGH2 that saturates its catalytic disposition by the thromboxane synthase, we also examined the formation of LG-lysine lactam adducts after activation of platelets with the physiological agonist, thrombin. As depicted in Fig. 4, LG-lysine adducts are formed following thrombin. Inhibition of formation of the adducts by indomethacin confirms that they are derived from oxygenation of arachidonic acid by the PGHS. Further evidence that the adducts are derived from PGH2 was obtained by examining the effect of dazoxiben, an inhibitor of thromboxane synthase. As shown in Fig. 5, inhibition of thromboxane synthase by dazoxiben led to an increase in the levels of LG-lysine lactam adduct (357 pg of lactam/1 × 109 platelets) by 2.1-fold compared with the control experiment in which no inhibitor was present. This report provides the first evidence that levuglandinyl adducts of proteins can be formed in a cell as a consequence of oxygenation of arachidonic acid by a PGHS. The immediate product of the PGHS, PGH2, is the substrate for synthases that catalyze its conversion to specific prostanoids. PGH2 also undergoes non-enzymatic rearrangement to several products, and the highly reactive ketoaldehydes, LGE2 and LGD2, account for ∼207 of these products. Even though levuglandinyl adducts of proteins have been demonstrated after exposure of the proteins to PGH2in vitro (2Boutaud O. Brame C.J. Salomon R.G. Roberts II, L.J. Oates J.A. Biochemistry. 1999; 38: 9389-9939Crossref PubMed Scopus (60) Google Scholar, 6Boutaud O. Brame C.J. Chaurand P. Li J. Rowlinson S.W. Crews B.C. Ji C. Marnett L.J. Caprioli R.M. Roberts II, L.J. Oates J.A. Biochemistry. 2001; 40: 6948-6955Crossref PubMed Scopus (31) Google Scholar), the competing enzymatic biotransformation of PGH2 in cells has provided a reason to question whether non-enzymatic rearrangement of PGH2 to LGE2 could occur in intact cells. To address this question, we chose to examine the platelet, in which there is robust biotransformation of PGH2 via the thromboxane synthase. Attention also has been focused on the platelet by the findings of Lecomte et al. (8Lecomte M. Lecocq R. Dumont J.E. Boeynaems J.M. J. Biol. Chem. 1990; 265: 5178-5187Abstract Full Text PDF PubMed Google Scholar) of uncharacterized, PGH2-derived adducts of at least 10 platelet proteins; one of these adducted proteins was PGHS-1, which we have shown to be adducted by levuglandin as a consequence of arachidonic acid oxygenation in vitro (6Boutaud O. Brame C.J. Chaurand P. Li J. Rowlinson S.W. Crews B.C. Ji C. Marnett L.J. Caprioli R.M. Roberts II, L.J. Oates J.A. Biochemistry. 2001; 40: 6948-6955Crossref PubMed Scopus (31) Google Scholar). Our finding that formation of the LG-lysine adduct of platelet proteins is inhibited by indomethacin indicates that its formation is a consequence of the oxygenation of arachidonic acid by the PGHS. The increased levels of LG-lysine adducts after treatment of the platelets with dazoxiben supports their origin from PGH2. The evidence that a levuglandinyl adduct of platelet proteins is derived from PGH2 provides support for the levuglandin pathway of arachidonic acid metabolism; it, of course, does not exclude the formation of adducts derived from other products of arachidonic acid. It may be concluded from these findings that LGE2 is formed in platelets and adducts platelet proteins even in the presence of an enzyme that uses PGH2as a substrate. The known properties of levuglandins provide a context for considering any possible functional consequences of the formation of such adducts of proteins. Clearly, adduct formation will add a lipophilic moiety to the protein. Considerable information on other lipid adducts of proteins indicates that they may alter processes such as localization, degradation, or function (13Buser C.A. Sigal C.T. Resh M.D. McLaughlin S. Biochemistry. 1994; 33: 13093-13101Crossref PubMed Scopus (165) Google Scholar). As an example specific to the levuglandins, formation of levuglandinyl adducts on proteins significantly reduces their clearance by the 20 S proteasome (14Davies S.S. Amarnath V. Montine K.S. Bernoud-Hubac N. Boutaud O. Montine T.J. Roberts II, L.J. FASEB J. 2002; 16: 715-717Crossref PubMed Scopus (95) Google Scholar). Also, the initial species of the levuglandinyl adducts are known to be highly reactive. This can lead to cross-linking between proteins and DNA (4Murthi K.K. Friedman L.R. Oleinick N.L. Salomon R.G. Biochemistry. 1993; 32: 4090-4097Crossref PubMed Scopus (58) Google Scholar) and between proteins and small molecules that contain amine groups (6Boutaud O. Brame C.J. Chaurand P. Li J. Rowlinson S.W. Crews B.C. Ji C. Marnett L.J. Caprioli R.M. Roberts II, L.J. Oates J.A. Biochemistry. 2001; 40: 6948-6955Crossref PubMed Scopus (31) Google Scholar). In addition, levuglandinyl adducts can produce intermolecular cross-linking between proteins (3Iyer R.S. Ghosh S. Salomon R.G. Prostaglandins. 1989; 37: 471-480Crossref PubMed Scopus (78) Google Scholar). For example, we have found that PGH2 accelerates the formation of amyloid औ oligomers in vitro (15Boutaud O. Ou J.J. Chaurand P. Caprioli R.M. Montine T.J. Oates J.A. J. Neurochem. 2002; 82: 1003-1006Crossref PubMed Scopus (60) Google Scholar). Because of the irreversible character of the adducts and cross-linked proteins, they have the potential to accumulate in cells over time. In conclusion, cyclooxygenase-dependent formation of levuglandinyl adducts of proteins occurs during platelet activation. This finding provides a basis for investigations that address the possible function of these reactive lipid adducts of proteins in platelets, as well as in other cells in which there is abundant or protracted production of PGH2. We thank Dr. Sheila Timmons for her valuable advice.
14
Olivier Boutaud, David M. Aronoff, Jacob H. Richardson et al. · Proceedings of the National Academy of Sciences · 2002 · 212 citations · Full text
A simple and efficient method for platelet isolation from their plasma
Michel Lagarde, P.A. Bryon, Michel Guichardant et al. · Thrombosis Research · 1980 · 184 citations
Medicine, Hematology, Hemostasis +12
Cynthia J. Brame, Robert G. Salomon, Jason D. Morrow et al. · Journal of Biological Chemistry · 1999 · 172 citations · Full text
Sean S. Davies, Ventkataraman Amarnath, Kathleen S. Montine et al. · The FASEB Journal · 2002 · 102 citations